Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II intraperitoneal catumaxomab consolidation in second or third complete remission of epithelial ovarian cancer
2010-018478-19Phase 2Completed
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Mar 2010
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of catumaxomab in Ovarian Epithelial Adenocarcinoma, sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: Progression-free survival. Started Mar 2010; status: completed.
02
Drugs
catumaxomab
03
Conditions
Ovarian Epithelial Adenocarcinoma
Beyond the preview
Go deeper on 2010-018478-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018478-19.